by The global Antimicrobial Susceptibility Testing Market is estimated to be valued at US$ 3751.4 Mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Antimicrobial susceptibility testing helps in determining the effectiveness of antimicrobial agents against microbes. It aids clinicians in choosing the most appropriate antimicrobial agent for treating an infection caused by a specific microorganism. Culturing of pathogens and assessing their sensitivity or resistance to different antimicrobial drugs is the primary workflow followed in susceptibility testing. The tests are carried out on various specimen sources including blood, urine, respiratory samples, and others.
Market Dynamics:
Increasing incidence of hospital-acquired infections and antimicrobial resistance: According to the WHO, antimicrobial resistance is one of the biggest threats to global health. The inappropriate use of antimicrobials has contributed significantly to the emergence and spread of drug-resistant pathogens. Antimicrobial susceptibility testing helps in appropriate treatment selection and reducing further development of drug resistance.
Technological advancements in susceptibility testing: Various technological advancements such as automation in susceptibility testing via solid- and liquid-phase microdilution susceptibility testing systems, imaging detection systems, and artificial intelligence-enabled diagnostic decision support systems have enhanced efficiency and reduced turnaround time in AST workflow.
Segment Analysis
The global antimicrobial susceptibility testing market is dominated by the products segment. The products segment accounted for the largest market share in 2020 owing to the rising adoption of automated systems, kits and reagents for antimicrobial susceptibility testing. Kits and reagents together contribute to more than 50% of the overall market. This is because these consumables need to be replenished regularly as they are used up with every test conducted.
PEST Analysis
Political: Government policies and initiatives like banning certain antibiotics and increasing standards for antibiotic stewardship are driving the adoption of antimicrobial susceptibility testing to optimize antibiotic usage.
Economic: The rising healthcare expenditure coupled with the growing incidence of infectious diseases is fueling the demand for antimicrobial susceptibility testing in developed economies.
Social: Increasing public awareness about AMR and prudent use of antibiotics is prompting healthcare facilities to conduct regular antimicrobial susceptibility testing.
Technological: Advancements in rapid automated testing methods, integrated software solutions and the development of new diagnostic assays are supporting the growth of the antimicrobial susceptibility testing market.
Key Takeaways
The global Antimicrobial Susceptibility Testing Market Demand is expected to witness high growth, exhibiting CAGR of 6.4% over the forecast period, due to increasing incidence of healthcare-associated infections and rising antibiotic resistance. North America dominated the market in 2023 owing to supportive government policies, high healthcare spending and presence of major market players in the region.
Regional analysis
North America is expected to continue dominating the market during the forecast period attributable to rising HAI rates, stringent government regulations and increasing adoption of rapid AST methods in clinical settings. Asia Pacific is projected to be the fastest growing regional market between 2023 and 2030 led by nations like India and China witnessing high prevalence of infectious diseases.
Key players operating in the antimicrobial susceptibility testing market are HiMedia Laboratories, Alifax S.r.l. Italy, Creative Diagnostics, Resistell AG, Danaher, Becton, Dickinson and Company, Merck KGaA, Bio-Rad Laboratories, Inc., Bruker, Nissui Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd.,Synbiosis, Mast Group Ltd., ELITechGroup, Flinn Scientific, CONDALAB, Accelerate Diagnostics, Inc. and Zhuhai DL Biotech Co., Ltd.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
